# A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

> **NCT04938180** · PHASE2 · TERMINATED · sponsor: **AmMax Bio, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Tenosynovial Giant Cell Tumor
- Pigmented Villonodular Synovitis
- TGCT
- PVNS - Pigmented Villonodular Synovitis

## Interventions

- **BIOLOGICAL:** AMB-05X

## Key facts

- **NCT ID:** NCT04938180
- **Lead sponsor:** AmMax Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-16
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-05-17
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Further enrollment was halted in November 2021, enrolled subjects completed the study. Sponsor stopped further recruitment in this intravenous study to focus on intra-articular route of administration in subjects with tenosynovial giant cell tumor.
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04938180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04938180, "A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04938180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*